January 4, 2019 12:01 PM EST
News Briefing

Aim­mune en­ters in­to loan agree­ment with KKR; Boehringer bags rights to sec­ond RNAi drug from Dicer­na

John Carroll

Editor & Founder

→ Hav­ing sub­mit­ted its FDA ap­pli­ca­tion to mar­ket its peanut al­ler­gy drug in De­cem­ber — in ef­fect leapfrog­ging ri­val DBV Tech­nolo­gies $DB­VT — Aim­mune Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times